Click on a filter below to refine your search. Remove a filter to broaden your search.
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
Developing AKI was associated with a significantly increased rate of subsequent dementia; the pattern was consistent across dementia types.